Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.

Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A.

Mult Scler. 2014 Apr;20(4):501-4. doi: 10.1177/1352458513495938. Epub 2013 Aug 28.

PMID:
23986097
2.

Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.

Viswanathan S, Wong AH, Quek AM, Yuki N.

J Neuroimmunol. 2015 May 15;282:92-6. doi: 10.1016/j.jneuroim.2015.03.021. Epub 2015 Mar 28.

PMID:
25903734
3.

Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M.

Mult Scler. 2016 Feb;22(2):185-92. doi: 10.1177/1352458515581438. Epub 2015 Apr 28.

4.

Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Bakker J, Metz L.

Can J Neurol Sci. 2004 May;31(2):265-7.

PMID:
15198456
5.

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.

Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J.

J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):918-21. doi: 10.1136/jnnp-2012-304774. Epub 2013 Mar 6.

PMID:
23467418
6.

Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.

Okada K, Tsuji S, Tanaka K.

Intern Med. 2007;46(19):1671-2. Epub 2007 Oct 1. No abstract available.

7.

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate.

Ramanathan RS, Malhotra K, Scott T.

BMC Neurol. 2014 Mar 15;14:51. doi: 10.1186/1471-2377-14-51.

8.

Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.

Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, Wong KS.

J Neurol Sci. 2013 Jan 15;324(1-2):38-9. doi: 10.1016/j.jns.2012.09.024. Epub 2012 Oct 2.

PMID:
23040959
9.

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.

Arch Neurol. 2008 Nov;65(11):1443-8. doi: 10.1001/archneur.65.11.noc80069. Epub 2008 Sep 8.

PMID:
18779415
10.

Neuromyelitis optica: potential roles for intravenous immunoglobulin.

Wingerchuk DM.

J Clin Immunol. 2013 Jan;33 Suppl 1:S33-7. doi: 10.1007/s10875-012-9796-7. Epub 2012 Sep 14. Review.

PMID:
22976554
11.

A review of cases of neuromyelitis optica.

Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL.

Neurologist. 2011 Mar;17(2):98-104. doi: 10.1097/NRL.0b013e31820a9d35. Review.

PMID:
21364364
12.

The effect of intravenous immunoglobulin on neuromyelitis optica.

Magraner MJ, Coret F, Casanova B.

Neurologia. 2013 Mar;28(2):65-72. doi: 10.1016/j.nrl.2012.03.014. Epub 2012 Jul 28. English, Spanish.

13.

[Trial of rituximab in three patients with neuromyelitis optica].

Imamura H, Tanaka M, Kitagawa N, Tahara M, Oono M, Tanaka K, Konishi T.

Rinsho Shinkeigaku. 2009 Aug;49(8):457-62. Japanese.

PMID:
19827593
14.

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.

Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.

JAMA Neurol. 2013 Sep 1;70(9):1110-7.

PMID:
23897062
15.

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder.

Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P.

Mult Scler. 2009 Apr;15(4):487-92. doi: 10.1177/1352458508100837.

PMID:
19324982
16.

[Neuromyelitis optica].

Nakashima I.

Rinsho Shinkeigaku. 2012;52(11):1231-3. Japanese.

PMID:
23196573
17.

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM.

Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26.

PMID:
23623397
18.

Analysis of the treatment of neuromyelitis optica.

Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N.

J Neurol Sci. 2015 Apr 15;351(1-2):31-5. doi: 10.1016/j.jns.2015.02.012. Epub 2015 Feb 13.

PMID:
25727350
19.

Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

Nobuyoshi S, Kanamori A, Matsumoto Y, Nakamura M.

Jpn J Ophthalmol. 2016 Sep;60(5):419-23. doi: 10.1007/s10384-016-0454-0. Epub 2016 Jun 7.

PMID:
27271761
20.

Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.

Mok CC, To CH, Mak A, Poon WL.

J Rheumatol. 2008 Jan;35(1):172-4.

PMID:
18176991

Supplemental Content

Support Center